Vertex Pharmaceuticals Changes in unrecognized tax benefits remained flat by 0.0% to 0.4% in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 87.6%, from 2.8% to 0.4%. Over 2 years (FY 2023 to FY 2025), Changes in unrecognized tax benefits shows a downward trend with a -35.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A lower impact suggests stability in tax positions and reduced exposure to tax-related litigation.
The percentage impact on the effective tax rate resulting from changes in unrecognized tax benefits. This metric isolate...
Standard component of the effective tax rate reconciliation table.
other_effective_income_tax_rate_reconciliation_tax_conti_ef495c| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | 3.4% | 11.3% | 1.4% |
| YoY Change | — | +232.4% | -87.6% |